The Prognostic Value of Human Papilloma Virus in Nasopharyngeal Carcinoma

Overview

It is well established that HPV infection has a casual and is a prognostic factor in several cancer types, including oropharynx. We wish to examine if HPV infection has a prognostic significance in nasopharyngeal carcinoma.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: July 2020

Clinical Trial Outcome Measures

Primary Measures

  • Overall survival
    • Time Frame: 6 months

Participating in This Clinical Trial

Inclusion Criteria

  • nasopharyngeal carcinoma patients treated in our institute between 2008-2018

Exclusion Criteria

  • missing clinical data
  • 2nd Head and neck primary cancer
  • very locally advanced or distant metastatic nasopharyngeal carcinoma
  • Prior radiation therapy to the head and neck region

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rambam Health Care Campus
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Eran S Fridman, MD, Principal Investigator, Rambam Health Care Campus
  • Overall Contact(s)
    • Eran S Fridman, MD, +972-4-7772480, eran.frid@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.